Revance Therapeutics (RVNC) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RVNC Stock Forecast

Revance Therapeutics stock forecast is as follows: an average price target of $6.66 (represents a 115.53% upside from RVNC’s last price of $3.09) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.

RVNC Price Target

The average price target for Revance Therapeutics (RVNC) is $6.66 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $6.66 to $6.66. This represents a potential 115.53% upside from RVNC's last price of $3.09.

RVNC Analyst Ratings

Hold

According to 9 Wall Street analysts, Revance Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for RVNC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (22.22%), 7 'Hold' (77.78%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Revance Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 17, 2024	Vamil Divan	Mizuho Securities	$6.66	$5.96	11.84%	115.53%
May 10, 2024	David Amsellem	Piper Sandler	$11.00	$3.73	194.51%	255.99%
May 10, 2024	Douglas Tsao	H.C. Wainwright	$11.00	$4.29	156.41%	255.99%
May 10, 2024	Vamil Divan	Mizuho Securities	$8.00	$3.73	114.47%	158.90%
Sep 20, 2023	Serge Belanger	Needham	$35.00	$13.48	159.64%	1032.69%
Jan 10, 2023		Needham	$38.00	$30.42	24.92%	1129.77%
Nov 16, 2022		Barclays	$37.00	$23.76	55.72%	1097.41%
Aug 25, 2022	Jacob Hughes	Wells Fargo	$24.00	$21.26	12.89%	676.70%

The latest Revance Therapeutics stock forecast, released on Sep 17, 2024 by Vamil Divan from Mizuho Securities, set a price target of $6.66, which represents a 11.84% increase from the stock price at the time of the forecast ($5.96), and a 115.53% increase from RVNC last price ($3.09).

Revance Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$9.16
Last Closing Price	$3.09	$3.09	$3.09
Upside/Downside	-100.00%	-100.00%	196.44%

In the current month, the average price target of Revance Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Revance Therapeutics's last price of $3.09. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 13, 2024	Barclays		Equal-Weight	Downgrade
Aug 13, 2024	H.C. Wainwright	Buy	Neutral	Downgrade
Aug 12, 2024	Needham	Buy	Hold	Downgrade
Aug 12, 2024	Piper Sandler	Overweight	Neutral	Downgrade
Aug 12, 2024	William Blair	Outperform	Market Perform	Downgrade
Aug 12, 2024	Guggenheim	Buy	Neutral	Downgrade
May 13, 2024	William Blair	Outperform	Outperform	Hold
May 10, 2024	Piper Sandler	Overweight	Overweight	Hold
May 10, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 20, 2023	Needham	Buy	Buy	Hold
Sep 20, 2023	Piper Sandler	Overweight	Overweight	Hold
Aug 16, 2023	Guggenheim		Buy	Initialise
Aug 16, 2023	Exane BNP Paribas		Neutral	Upgrade
Sep 22, 2022	Cowen & Co.		Outperform	Initialise
Sep 22, 2022	RBC Capital		Outperform	Initialise
Sep 09, 2022	Needham	Buy	Buy	Hold
Aug 10, 2022	Needham	Buy	Buy	Hold

Revance Therapeutics's last stock rating was published by Barclays on Sep 13, 2024. The company Downgrade its RVNC rating from "null" to "Equal-Weight".

Revance Therapeutics Financial Forecast

Revance Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$56.78M	$58.13M	$49.33M	$49.92M	$29.02M	$28.37M	$25.26M	$25.95M	$19.75M	$18.80M	$13.30M	$11.13M	$3.83M	$299.00K	$58.00K	$89.00K	$46.00K	-	$278.00K	$193.00K	$75.00K
Avg Forecast	$90.60M	$84.80M	$82.90M	$72.00M	$72.94M	$68.17M	$66.30M	$56.40M	$62.12M	$58.40M	$58.71M	$46.21M	$44.95M	$28.24M	$28.15M	$23.76M	$23.91M	$20.07M	$15.50M	$10.42M	$9.08M	$1.84M	$508.13K	$169.50K	$2.52M	$412.50K	$828.50K	$1.35M	$141.27K	$67.82K
High Forecast	$95.72M	$89.59M	$87.58M	$74.81M	$76.40M	$68.26M	$66.30M	$56.40M	$74.32M	$58.87M	$62.03M	$48.82M	$47.49M	$28.24M	$28.15M	$23.76M	$23.91M	$20.07M	$15.50M	$10.42M	$9.08M	$1.84M	$508.13K	$169.50K	$2.52M	$412.50K	$828.50K	$1.35M	$169.52K	$81.38K
Low Forecast	$84.41M	$79.01M	$77.24M	$69.19M	$67.45M	$68.08M	$66.30M	$56.40M	$58.24M	$57.94M	$54.70M	$43.06M	$41.88M	$28.24M	$28.15M	$23.76M	$23.91M	$20.07M	$15.50M	$10.42M	$9.08M	$1.84M	$508.13K	$169.50K	$2.52M	$412.50K	$828.50K	$1.35M	$113.01K	$54.25K
# Analysts	1	1	1	2	3	1	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9	9	9	5	5	5	5	12	13
Surprise %	-	-	-	-	-	-	-	-	-	0.97%	0.99%	1.07%	1.11%	1.03%	1.01%	1.06%	1.09%	0.98%	1.21%	1.28%	1.23%	2.08%	0.59%	0.34%	0.04%	0.11%	-	0.21%	1.37%	1.11%

Revance Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $62.12M, with a low forecast of $58.24M, and a high forecast of $74.32M. RVNC's average Quarter revenue forecast represents a 9.41% increase compared to the company's last Quarter revenue of $56.78M (Sep 23).

Revance Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9	9	9	5	5	5	5	12	13
EBITDA	-	-	-	-	-	-	-	-	-	$-39.74M	$-63.36M	$-53.29M	$-56.16M	$-67.42M	$-50.89M	$-56.99M	$-56.11M	$-67.66M	$-65.58M	$-65.84M	$-72.30M	$-73.14M	$-54.92M	$-58.95M	$-44.57M	$-40.67M	$-36.60M	$-34.68M	$-34.60M	$-26.61M
Avg Forecast	$-90.60M	$-84.80M	$-82.90M	$-72.00M	$-72.94M	$-68.17M	$-66.30M	$-66.74M	$-62.12M	$-58.40M	$-58.71M	$-60.67M	$-66.04M	$-27.59M	$-27.50M	$-55.15M	$-23.36M	$-19.61M	$-15.15M	$-66.44M	$-8.87M	$-1.80M	$-496.40K	$-42.57M	$-2.47M	$-402.98K	$-809.38K	$-35.47M	$-21.93M	$-23.79M
High Forecast	$-84.41M	$-79.01M	$-77.24M	$-69.19M	$-67.45M	$-68.08M	$-66.30M	$-53.39M	$-58.24M	$-57.94M	$-54.70M	$-48.54M	$-52.83M	$-27.59M	$-27.50M	$-44.12M	$-23.36M	$-19.61M	$-15.15M	$-53.15M	$-8.87M	$-1.80M	$-496.40K	$-34.06M	$-2.47M	$-402.98K	$-809.38K	$-28.38M	$-17.55M	$-19.03M
Low Forecast	$-95.72M	$-89.59M	$-87.58M	$-74.81M	$-76.40M	$-68.26M	$-66.30M	$-80.08M	$-74.32M	$-58.87M	$-62.03M	$-72.80M	$-79.24M	$-27.59M	$-27.50M	$-66.19M	$-23.36M	$-19.61M	$-15.15M	$-79.73M	$-8.87M	$-1.80M	$-496.40K	$-51.09M	$-2.47M	$-402.98K	$-809.38K	$-42.57M	$-26.32M	$-28.55M
Surprise %	-	-	-	-	-	-	-	-	-	0.68%	1.08%	0.88%	0.85%	2.44%	1.85%	1.03%	2.40%	3.45%	4.33%	0.99%	8.15%	40.65%	110.64%	1.38%	18.07%	100.94%	45.22%	0.98%	1.58%	1.12%

undefined analysts predict RVNC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Revance Therapeutics's previous annual EBITDA (undefined) of $NaN.

Revance Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9	9	9	5	5	5	5	12	13
Net Income	-	-	-	-	-	-	-	-	-	$-141.18M	$-67.32M	$-66.05M	$-144.55M	$-84.69M	$-61.50M	$-64.39M	$-64.67M	$-74.38M	$-72.20M	$-71.64M	$-78.31M	$-81.26M	$-60.59M	$-61.93M	$-45.33M	$-41.41M	$-37.39M	$-35.30M	$-35.04M	$-27.16M
Avg Forecast	$-8.28M	$-10.99M	$-18.45M	$-25.17M	$-26.56M	$-28.04M	$-37.51M	$-75.29M	$-68.02M	$-72.32M	$-65.99M	$-68.44M	$-74.27M	$-83.00M	$-79.20M	$-62.22M	$-91.54M	$-100.65M	$-99.92M	$-72.30M	$-122.09M	$-108.54M	$-101.51M	$-44.73M	$-98.94M	$-99.40M	$-93.07M	$-36.12M	$-22.21M	$-24.28M
High Forecast	$-7.55M	$-10.02M	$-16.81M	$-22.93M	$-23.99M	$-25.55M	$-34.18M	$-60.23M	$-64.58M	$-65.90M	$-60.14M	$-54.75M	$-59.41M	$-83.00M	$-79.20M	$-49.78M	$-91.54M	$-100.65M	$-99.92M	$-57.84M	$-122.09M	$-108.54M	$-101.51M	$-35.78M	$-98.94M	$-99.40M	$-93.07M	$-28.89M	$-17.77M	$-19.42M
Low Forecast	$-8.89M	$-11.80M	$-19.80M	$-27.02M	$-29.13M	$-30.09M	$-40.27M	$-90.34M	$-71.46M	$-77.62M	$-70.84M	$-82.13M	$-89.12M	$-83.00M	$-79.20M	$-74.67M	$-91.54M	$-100.65M	$-99.92M	$-86.76M	$-122.09M	$-108.54M	$-101.51M	$-53.68M	$-98.94M	$-99.40M	$-93.07M	$-43.34M	$-26.65M	$-29.14M
Surprise %	-	-	-	-	-	-	-	-	-	1.95%	1.02%	0.97%	1.95%	1.02%	0.78%	1.03%	0.71%	0.74%	0.72%	0.99%	0.64%	0.75%	0.60%	1.38%	0.46%	0.42%	0.40%	0.98%	1.58%	1.12%

Revance Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RVNC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Revance Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9	9	9	5	5	5	5	12	13
SG&A	-	-	-	-	-	-	-	-	-	$67.73M	$77.38M	$66.01M	$65.24M	$64.74M	$46.83M	$43.94M	$45.20M	$51.77M	$49.68M	$51.84M	$55.67M	$50.75M	$30.28M	$21.22M	$18.77M	$16.74M	$13.60M	$12.91M	$13.62M	$7.75M
Avg Forecast	$3.00B	$2.81B	$2.74B	$2.38B	$2.42B	$2.26B	$2.20B	$51.42M	$2.06B	$1.93B	$1.94B	$1.53B	$1.49B	$934.95M	$931.89M	$786.84M	$791.68M	$664.59M	$513.36M	$344.98M	$300.79M	$60.98M	$16.82M	$5.61M	$83.57M	$13.66M	$27.43M	$44.68M	$4.68M	$2.25M
High Forecast	$3.17B	$2.97B	$2.90B	$2.48B	$2.53B	$2.26B	$2.20B	$61.70M	$2.46B	$1.95B	$2.05B	$1.62B	$1.57B	$934.95M	$931.89M	$786.84M	$791.68M	$664.59M	$513.36M	$344.98M	$300.79M	$60.98M	$16.82M	$5.61M	$83.57M	$13.66M	$27.43M	$44.68M	$5.61M	$2.69M
Low Forecast	$2.79B	$2.62B	$2.56B	$2.29B	$2.23B	$2.25B	$2.20B	$41.13M	$1.93B	$1.92B	$1.81B	$1.43B	$1.39B	$934.95M	$931.89M	$786.84M	$791.68M	$664.59M	$513.36M	$344.98M	$300.79M	$60.98M	$16.82M	$5.61M	$83.57M	$13.66M	$27.43M	$44.68M	$3.74M	$1.80M
Surprise %	-	-	-	-	-	-	-	-	-	0.04%	0.04%	0.04%	0.04%	0.07%	0.05%	0.06%	0.06%	0.08%	0.10%	0.15%	0.19%	0.83%	1.80%	3.78%	0.22%	1.23%	0.50%	0.29%	2.91%	3.45%

Revance Therapeutics's average Quarter SG&A projection for Dec 23 is $2.06B, based on 8 Wall Street analysts, with a range of $1.93B to $2.46B. The forecast indicates a 2936.61% rise compared to RVNC last annual SG&A of $67.73M (Sep 23).

Revance Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9	9	9	5	5	5	5	12	13
EPS	-	-	-	-	-	-	-	-	-	$-1.63	$-0.00	$-0.81	$-1.80	$-1.17	$-0.88	$-0.94	$-0.95	$-1.10	$-1.07	$-1.08	$-1.24	$-1.34	$-1.12	$-1.15	$-0.99	$-0.96	$-0.86	$-0.85	$-0.97	$-0.94
Avg Forecast	$-0.08	$-0.11	$-0.18	$-0.24	$-0.25	$-0.27	$-0.36	$-0.46	$-0.65	$-0.69	$-0.63	$-0.67	$-0.76	$-0.80	$-0.76	$-0.80	$-0.88	$-0.97	$-0.96	$-1.03	$-1.18	$-1.04	$-0.98	$-0.87	$-0.95	$-0.96	$-0.90	$-0.87	$-0.45	$-0.76
High Forecast	$-0.07	$-0.10	$-0.16	$-0.22	$-0.23	$-0.25	$-0.33	$-0.42	$-0.62	$-0.63	$-0.58	$-0.61	$-0.69	$-0.80	$-0.76	$-0.80	$-0.88	$-0.97	$-0.96	$-1.03	$-1.18	$-1.04	$-0.98	$-0.87	$-0.95	$-0.96	$-0.90	$-0.87	$-0.36	$-0.61
Low Forecast	$-0.09	$-0.11	$-0.19	$-0.26	$-0.28	$-0.29	$-0.39	$-0.50	$-0.69	$-0.74	$-0.68	$-0.72	$-0.82	$-0.80	$-0.76	$-0.80	$-0.88	$-0.97	$-0.96	$-1.03	$-1.18	$-1.04	$-0.98	$-0.87	$-0.95	$-0.96	$-0.90	$-0.87	$-0.54	$-0.91
Surprise %	-	-	-	-	-	-	-	-	-	2.35%	0.00%	1.21%	2.37%	1.46%	1.15%	1.18%	1.08%	1.14%	1.11%	1.05%	1.05%	1.28%	1.15%	1.32%	1.04%	1.00%	0.96%	0.97%	2.16%	1.24%

According to undefined Wall Street analysts, Revance Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RVNC previous annual EPS of $NaN (undefined).

Revance Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$2.37	$33.86	1328.69%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
IMCR	Immunocore	$29.40	$70.20	138.78%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
RVNC	Revance Therapeutics	$3.07	$6.66	116.94%	Hold
APLS	Apellis Pharmaceuticals	$34.53	$70.80	105.04%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
DMAC	DiaMedica Therapeutics	$5.20	$8.50	63.46%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
ETNB	89bio	$7.98	$12.00	50.38%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy
NUVL	Nuvalent	$88.10	$114.80	30.31%	Buy
BPMC	Blueprint Medicines	$96.48	$122.60	27.07%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy

RVNC Forecast FAQ

Is Revance Therapeutics a good buy?

No, according to 9 Wall Street analysts, Revance Therapeutics (RVNC) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 22.22% of RVNC's total ratings.

What is RVNC's price target?

Revance Therapeutics (RVNC) average price target is $6.66 with a range of $6.66 to $6.66, implying a 115.53% from its last price of $3.09. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Revance Therapeutics stock go up soon?

According to Wall Street analysts' prediction for RVNC stock, the company can go up by 115.53% (from the last price of $3.09 to the average price target of $6.66), up by 115.53% based on the highest stock price target, and up by 115.53% based on the lowest stock price target.

Can Revance Therapeutics stock reach $5?

RVNC's average twelve months analyst stock price target of $6.66 supports the claim that Revance Therapeutics can reach $5 in the near future.

What are Revance Therapeutics's analysts' financial forecasts?

Revance Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $263.81M (high $267.36M, low $258.22M), average EBITDA is $-274M (high $-255M, low $-291M), average net income is $-167M (high $-144M, low $-190M), average SG&A $6.92B (high $7.05B, low $6.72B), and average EPS is $-1.346 (high $-1.225, low $-1.451). RVNC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $330.3M (high $347.69M, low $309.86M), average EBITDA is $-330M (high $-310M, low $-348M), average net income is $-62.892M (high $-57.31M, low $-67.51M), average SG&A $10.94B (high $11.51B, low $10.26B), and average EPS is $-0.603 (high $-0.55, low $-0.648).

Did the RVNC's actual financial results beat the analysts' financial forecasts?

Based on Revance Therapeutics's last annual report (Dec 2022), the company's revenue was $132.56M, beating the average analysts forecast of $125.1M by 5.97%. Apple's EBITDA was $-242M, beating the average prediction of $-176M by 37.07%. The company's net income was $-356M, beating the average estimation of $-299M by 19.33%. Apple's SG&A was $223.93M, missing the average forecast of $4.14B by -94.59%. Lastly, the company's EPS was $-4.9, beating the average prediction of $-3.118 by 57.16%. In terms of the last quarterly report (Sep 2023), Revance Therapeutics's revenue was $56.78M, missing the average analysts' forecast of $58.4M by -2.79%. The company's EBITDA was $-39.744M, missing the average prediction of $-58.404M by -31.95%. Revance Therapeutics's net income was $-141M, beating the average estimation of $-72.315M by 95.22%. The company's SG&A was $67.73M, missing the average forecast of $1.93B by -96.50%. Lastly, the company's EPS was $-1.63, beating the average prediction of $-0.694 by 134.90%